Summary: The 2023 Guidelines of the European Society of Hypertension (ESH) translates clinical achievements into practice use and provide recommendations for clinical BP measurements, CV risk assessment, secondary forms of hypertension and also updates on thresholds and targets of antihypertensive drug treatment. ESH guidelines also provide practicing physicians and hypertension experts with the update on preferred use RAS blockers, CCBs and thiazide / thiazide-like diuretics and their various combinations for BP-lowering treatment. Finally, contain recommendations for management of hypertension coexisting with various comorbidities, including HF, CKD, CAD AF and other clinical conditions. The current review also hightlights the relevnce of lisinopril, ACEi with proven efficacy and safety, in the treatment of hypertension and other CV diseases, including CAD, HF and CKD. In all studies performed so far lisinopril was shown not only to effectively lower BP, but alo positively affect target organ damage and CV risk.